As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
(1) Complete absorption (preferably passive absorption), bioavailability > 50% and minimal variation;
(2) AUC is proportional to dose, and there is a clear PK/PD correlation;
(3) Quickly reaches the target organ and do not accumulate outside it;
(4) PPB < 90%, unaffected by concentration and time;
(5) Plasma clearance CL < 30% of Qh, cleared through various routes;
(6) Age, race, gender, disease state, etc. have little effect on CL; low quantity of metabolites and no production of reactive metabolites;
(7) metabolite quantity is low and no reactive metabolites are produced;
(8) Does not inhibit or induce major drug metabolizing enzymes and transporters, and is not affected by food;
(9) T1/2>6hr in human body, reducing the dosing frequency and improving compliance.